# Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer

> **NCT02293954** · NA · ACTIVE_NOT_RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 20 (actual)

## Conditions studied

- Breast Cancer
- Colon Cancer
- Extrahepatic Bile Duct Cancer
- Gallbladder Cancer
- Gastrointestinal Cancer
- Liver and Intrahepatic Biliary Tract Cancer
- Lung Cancer
- Metastatic Cancer
- Pancreatic Cancer
- Rectal Cancer
- Thyroid Gland Medullary Carcinoma
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **PROCEDURE:** radionuclide imaging
- **PROCEDURE:** positron emission tomography
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study
- **DRUG:** Cu 64 anti-CEA monoclonal antibody M5A IV

## Key facts

- **NCT ID:** NCT02293954
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-11-11
- **Primary completion:** 2022-03-06
- **Final completion:** 2026-08-11
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-11-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02293954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02293954, "Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02293954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*